Preview Mode Links will not work in preview mode

This Week in Cardiology

Dec 3, 2021

The AMAZE trial of left atrial appendage isolation, non-statin oral lipid lowering drugs, EHR alerts, non-MD care, and obesity are the topics John Mandrola, MD, discusses in this week’s podcast. To read a partial transcript or to comment, visit:

I – aMAZE Trial

- No Advantage Shown for LAA Ligation as Adjunct to Pulmonary Vein Isolation

- Safety and Procedural Success of Left Atrial Appendage Exclusion With the Lariat Device

- Left Atrial Appendage Isolation in Patients With Longstanding Persistent AF Undergoing Catheter Ablation: BELIEF Trial

II – Non-Statin Lipid Lowering

- Obicetrapib: CETP Inhibitor Impresses in LDL Lowering

- Daily Oral PCSK9 Inhibitor Encouraging in Phase 1 Trials

III – EHR Alerts and Prognosis

- EHR Alerts Have No Impact on Inpatient HF Treatment or Outcomes

- REVeAL-HF: Design and Rationale of a Pragmatic Randomized Controlled Trial Embedded Within Routine Clinical Practice

IV – Non-MD Care Models

- Remote Non-Physician Care Helps BP, LDL Control

- A Remotely Delivered Hypertension and Lipid Program in 10,000 Patients Across a Diverse Health Care Network!/9349/presentation/18153

V – Obesity in the Young

- Obesity Rates Soar in Early Adulthood in the US

- Trends in Obesity Prevalence Among Adults Aged 18 Through 25 Years, 1976-2018


- Doubting the BELIEF Trial on LAA Isolation

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact